Free Trial
NASDAQ:KOD

Kodiak Sciences Q1 2025 Earnings Report

Kodiak Sciences logo
$3.33 -0.61 (-15.48%)
As of 05/15/2025 04:00 PM Eastern

Kodiak Sciences EPS Results

Actual EPS
-$1.09
Consensus EPS
-$0.89
Beat/Miss
Missed by -$0.20
One Year Ago EPS
N/A

Kodiak Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kodiak Sciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Kodiak Sciences' Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Thursday, May 22, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Kodiak Sciences Earnings Headlines

Silver Is the New Oil—And the World’s Running Dry
Elon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to SpaceX to AI. And now, whispers are growing that his next move could be in silver. Why? Because silver is the lifeblood of EVs, solar panels, and AI tech.
See More Kodiak Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email.

About Kodiak Sciences

Kodiak Sciences (NASDAQ:KOD), a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

View Kodiak Sciences Profile

More Earnings Resources from MarketBeat